Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;19 Suppl 9(Suppl 9):S126-S131.
doi: 10.1002/alz.13353. Epub 2023 Jun 30.

Developments in understanding early onset Alzheimer's disease

Percy Griffin  1 , Liana Apostolova  2 , Bradford C Dickerson  3 , Gil Rabinovici  4 , Stephen Salloway  5 , Katie Brandt  3 , Joseph Masdeu  6 , Dustin Hammers  7 , Srilatha Raghuram  1 , Stephen Hall  1 , Maria C Carrillo  1
Affiliations

Developments in understanding early onset Alzheimer's disease

Percy Griffin et al. Alzheimers Dement. 2023 Nov.

Abstract

On September 25 and 26, 2021, the Alzheimer's Association hosted the first meeting focused on people with early-onset Alzheimer's disease (EOAD)-sometimes referred to as younger onset Alzheimer's disease (AD). Though a diagnosis of AD can be devastating at any age, those with a younger onset-defined as symptoms developing prior to 65 years of age-face unique challenges. EOAD occurs when people are in the prime of their lives, often with multiple responsibilities including careers, community activities, and raising children and caring for older family members. These challenges warrant special consideration and study, yet people with EOAD are often excluded from AD research because of their atypical age of onset. To help fill this gap, we designed and launched the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) to enroll and follow 500 people with EOAD from > 15 sites in the United States, which the National Institute on Aging funded in 2018. The September 2021 meeting was designed to inform people with EOAD and their family members and caregivers about the latest research on the biology of EOAD, treatments in the pipeline, practical considerations about legal and financial arrangements for families, and the support networks available to them. More than 217 registrants attended.

Keywords: Longitudinal Early-Onset Alzheimer's Disease Study; early-onset dementia; natural history; neurodegenerative disease.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

Percy Griffin, Stephen Hall, Srilatha Raghuram, and Maria C. Carrillo have nothing to disclose except they are full-time employees of the Alzheimer’s Association. Liana Apostolova has served as a paid consultant to Biogen, Two Labs, IQVIA, FL Dept Health, Genentech, NIH Biobank, Eli Lilly, GE Healthcare, Eisai, Roche Diagnostics, and Alnylam. She has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events for AAN, MillerMEd NACC CME, CME Institute, APhA, ASIM, Purdue University, Mayo Clinic, MJH Physician Education Resource, Ohio State University, and PeerView. She has participated on the Data Safety Monitoring Board or Advisory Board for IQVIA, NIA R01 AG061111, UAB Nathan Schock Center, New Mexico Exploratory ADRC, and FDA. She has leadership or fiduciary roles in Med Sci Council for Alzheimer’s Association Greater Indiana Chapter, Alzheimer’s Association Science Program Committee, FDA PCNS Advisory Committee, and Beeson Program Committee. She owns stock in Cassava Neurosciences and Golden Seeds. She has received equipment, materials, drugs, medical writing, gifts, or other services from AVID Pharmaceuticals, Life Molecular Imaging, and Roche Diagnostics. Brad Dickerson has received royalties or licenses from Cambridge University Press, Oxford University Press, and Elsevier. He has received consulting fees from Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Takeda, and Wave Lifesciences. He has participated on a Data Safety Monitoring Board or Advisory Board for Merck and Lilly. He has a leadership or fiduciary as the Chair of the AFTD Med/Sci Council. Dustin Hammers has received grants or contracts from the Davos Alzheimer’s Collaborative. Gil Rabinovici has received grants or contracts from Avid Radiopharmaceuticals, Genentech, GE Healthcare, Life Molecular Imaging, Alzheimer’s Association, Rainwater Charitable foundation, and American College of Radiology. He has been paid consulting fees from Alector, Eli Lilly, Merck, Genentech, GE Healthcare, and Roche. He has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscripts or writing or educa events from Clearview and Miller Medical. He has participated on a Data Safety Monitoring Board or Advisory Board for Johnson and Johnson. Stephen Salloway has received grants or contracts from Avid, Lilly, Biogen, Genentech, Roche, Eisai, and Novartis. He has been paid consulting fees from Lilly, Biogen, Roche, Genetech, Eisai, Bolden, Amylyx, Novo Nordisk, Prothena, Ono, and Alnylam. He has participated on a Data Safety Monitoring Board or Advisory Board for Biogen. Katherine Brandt has been paid consulting fees from Wave Life Sciences. She has received payments or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Bob’s Last Marathon. She is a Board Member of the Kendall Square Orchestra. Author disclosures are available in the Supporting Information

References

    1. Polsinelli AJ, Apostolova LG. Atypical Alzheimer disease variants. CONTINUUM: Lifelong Learn Neurol 2022;28(3):676. doi:10.1212/CON.0000000000001082 - DOI - PMC - PubMed
    1. Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol 2021;20(3):222–234. doi:10.1016/S1474-4422(20)30440-3 - DOI - PMC - PubMed
    1. Arboleda-Velasquez JF, Lopera F, O’Hare M, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med 2019;25(11):1680–1683. doi:10.1038/s41591-019-0611-3 - DOI - PMC - PubMed
    1. Apostolova LG, Aisen P, Eloyan A, et al. The longitudinal early-onset Alzheimer’s disease Study (LEADS): framework and methodology. Alzheimers Dement 2021;17(12):2043–2055. doi:10.1002/alz.12350 - DOI - PMC - PubMed
    1. Rabinovici GD. Late-onset Alzheimer disease. Continuum (Minneap Minn) 2019;25(1):14–33. doi:10.1212/CON.0000000000000700 - DOI - PMC - PubMed

Publication types